Astragalus (TA-65) vs Fisetin
Two longevity supplements, two different mechanisms — lengthen the telomere, or clear the senescent cell. Both are sold well ahead of their evidence.
Short answer
Astragalus has the stronger evidence for its marketed use, with human clinical data against only preclinical or minimal evidence for fisetin, resting mostly on animal or lab work. Someone focused on telomerase activation, immune support and longevity has trial data to go on with astragalus; fisetin, marketed for senolytic use and anti-aging, is still an early-research option.
Astragalus (TA-65)
TA-65, a purified astragalus-root extract, has a real open-label human trial showing telomerase activation and improved biomarkers over a multi-year health-maintenance program — encouraging but industry-linked, uncontrolled, and a long way from a randomized longevity outcome.
Full Astragalus (TA-65) evidence reviewFisetin
The most potent senolytic flavonoid in mice, with lifespan data — but the one human trial to report a clinical outcome (ROPE, knee osteoarthritis) was null; other senolytic-hypothesis trials remain unpublished.
Full Fisetin evidence reviewAstragalus (TA-65) vs Fisetin: head to head
- FDA status / approved use
Astragalus (TA-65)
Sold as an herbal botanical and purified supplement; not a proven longevity therapyFisetin
Sold as a dietary supplement, not an approved drug; senolytic use is investigational- Marketed for
Astragalus (TA-65)
Telomerase activation, immune support, longevityFisetin
Senolytic, anti-aging- Outcome areas
Astragalus (TA-65)
Cellular senescence; Longevity / lifespan; Immune function / inflammationFisetin
Cellular senescence; Longevity / lifespan; Joint / bone health- Evidence grade
Astragalus (TA-65)
Clinical dataFisetin
Preclinical / minimal- How it works
Astragalus (TA-65)
Its saponin cycloastragenol activates telomerase, the enzyme that rebuilds chromosome caps, in cellsFisetin
Senolytic: clears senescent 'zombie' cells, shown mainly in mice- Route and dosing
Astragalus (TA-65)
Oral capsuleFisetin
Oral supplement, often taken in high intermittent doses- Headline human result
Astragalus (TA-65)
As a kidney-disease add-on, 24-hour proteinuria fell by 0.53 g across 10 low-quality trials in a 2014 Cochrane reviewFisetin
No significant benefit for knee pain, function or cartilage at three months in the 2025 ROPE osteoarthritis RCT- Strongest evidence
Astragalus (TA-65)
TA-65 health maintenance program, Rejuvenation Res 2011Astragalus (TA-65) evidence reviewPubMed 20822369Fisetin
Mouse senolytic, EBioMedicine 2018. Little or no controlled human outcome data for the marketed useFisetin evidence reviewPubMed 30279143- Key safety signal
Astragalus (TA-65)
Telomerase activation raises an unresolved cancer concern; caution with immunosuppressants and autoimmune diseaseFisetin
Looks safe as a food compound; long-term safety of high senolytic doses is not established- How it is obtained
Astragalus (TA-65)
Over the counter as a dietary supplementFisetin
Over the counter as a dietary supplement
| Astragalus (TA-65) | Fisetin | |
|---|---|---|
| FDA status / approved use | Sold as an herbal botanical and purified supplement; not a proven longevity therapy | Sold as a dietary supplement, not an approved drug; senolytic use is investigational |
| Marketed for | Telomerase activation, immune support, longevity | Senolytic, anti-aging |
| Outcome areas | Cellular senescence; Longevity / lifespan; Immune function / inflammation | Cellular senescence; Longevity / lifespan; Joint / bone health |
| Evidence grade | Clinical data | Preclinical / minimal |
| How it works | Its saponin cycloastragenol activates telomerase, the enzyme that rebuilds chromosome caps, in cells | Senolytic: clears senescent 'zombie' cells, shown mainly in mice |
| Route and dosing | Oral capsule | Oral supplement, often taken in high intermittent doses |
| Headline human result | As a kidney-disease add-on, 24-hour proteinuria fell by 0.53 g across 10 low-quality trials in a 2014 Cochrane review | No significant benefit for knee pain, function or cartilage at three months in the 2025 ROPE osteoarthritis RCT |
| Strongest evidence | TA-65 health maintenance program, Rejuvenation Res 2011Astragalus (TA-65) evidence reviewPubMed 20822369 | Mouse senolytic, EBioMedicine 2018. Little or no controlled human outcome data for the marketed useFisetin evidence reviewPubMed 30279143 |
| Key safety signal | Telomerase activation raises an unresolved cancer concern; caution with immunosuppressants and autoimmune disease | Looks safe as a food compound; long-term safety of high senolytic doses is not established |
| How it is obtained | Over the counter as a dietary supplement | Over the counter as a dietary supplement |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
- Preclinical / minimal:
- Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.
Our verdict
TA-65, a purified astragalus-root extract, has a real open-label human trial reporting telomerase activation and improved biomarkers across a multi-year health-maintenance program — encouraging, but industry-linked, uncontrolled, and a long way from a randomized longevity outcome. Fisetin is the most potent senolytic flavonoid in mice and has mouse lifespan data behind it, yet the one human trial to report a clinical outcome, ROPE in knee osteoarthritis, was null, and other senolytic-hypothesis trials remain unpublished. Neither has a randomized human result supporting a longevity claim, and they have never been compared.
Astragalus (TA-65) fits if
You want the telomerase hypothesis and accept an uncontrolled, industry-linked human study as the best evidence available for it.
Fisetin fits if
You follow the senolytic hypothesis and accept that the mouse data is strong while the human read-outs so far are null or unpublished.
Astragalus (TA-65) vs Fisetin: common questions
- Is either astragalus or fisetin FDA-approved?
- No. Astragalus is sold as an herbal botanical and purified supplement; not a proven longevity therapy. Fisetin is sold as a dietary supplement, not an approved drug; senolytic use is investigational.
- Which has stronger human evidence, astragalus or fisetin?
- Astragalus. It has human clinical data (key source: TA-65 health maintenance program, Rejuvenation Res 2011), while fisetin has only preclinical or minimal evidence (key source: Mouse senolytic, EBioMedicine 2018).
- What are the main safety concerns with astragalus and fisetin?
- With astragalus, telomerase activation raises an unresolved cancer concern; caution with immunosuppressants and autoimmune disease. Fisetin looks safe as a food compound; long-term safety of high senolytic doses is not established.
Key studies behind each
Astragalus (TA-65)
- Fauce SR, Jamieson BD, Chin AC, et al. (2008). Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes. J Immunol. PubMed 18981163
- Harley CB, Liu W, Blasco M, et al. (2011). A natural product telomerase activator as part of a health maintenance program. Rejuvenation Res. PubMed 20822369
- Harley CB, Liu W, Flom PL, Raffaele JM. (2013). A natural product telomerase activator as part of a health maintenance program: metabolic and cardiovascular response. Rejuvenation Res. PubMed 23808324
- Maier R, Bawamia B, Bennaceur K, et al. (2020). Telomerase activation to reverse immunosenescence in elderly patients with acute coronary syndrome: protocol for a randomized pilot trial. JMIR Res Protoc. PubMed 32965237
Fisetin
- Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. (2018). Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. PubMed 30279143
- Murray KO, Mahoney SA, Ludwig KR, et al. (2025). Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging. Aging Cell. PubMed 40437670
- Silva M, Wacker DA, Driver BE, et al. (2024). Senolytics To slOw Progression of Sepsis (STOP-Sepsis) in elderly patients: Study protocol for a multi-center, randomized, adaptive allocation clinical trial. Trials. PubMed 39434114
- Ji J, Crespi CM, Yee L, et al. (2026). A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design. Ther Adv Med Oncol. PubMed 41835341
The full evidence reviews
- Astragalus & TA-65: a real telomerase activator, an unproven anti-aging claim
Astragalus is an immune-tonic herb whose saponin cycloastragenol genuinely activates telomerase in cells — but the longevity pitch rests on small, industry-linked human studies, while the better clinical data sit in kidney and heart disease.
Updated August 2026
- Fisetin: a powerful senolytic in mice, unproven in humans
A dietary flavonoid that's the most potent senolytic of its class and extends lifespan in mice — but the human trials that would test the senolytic claim are still ongoing, with no published outcomes.
Updated August 2026